gemcitabine has been researched along with on 01910 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, A; Chan, F; Cosenza, SC; Cusatis, G; Donehower, RC; Hidalgo, M; Jimeno, A; Kulesza, P; Ramana Reddy, MV; Reddy, EP; Rudek, MA; Solomon, A; Wheelhouse, J; Zhang, X; Zhao, M | 1 |
| Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F | 1 |
| Aisner, DL; Bajaj, R; Baranda, JC; Bathini, V; Berlin, J; Boles, J; Cho, JK; Cohen, DJ; Cohen, SJ; Coveler, L; Cusnir, M; Fanta, P; Fehrenbacher, L; Gomes, CL; Granfortuna, J; Jimeno, A; Ma, WW; Maguire, R; Maniar, M; McRee, AJ; Menter, AR; Messersmith, WA; Nazemzadeh, R; O'Neil, BH; Olowokure, OO; Phillip, P; Radford, J; Rarick, M; Scott, AJ; Tejani, MA; Wilhelm, F | 1 |
| Cavaletti, G; Celio, L; Damian, S; Malacrida, A; Mazzaferro, V; Miloso, M; Rigolio, R | 1 |
2 trial(s) available for gemcitabine and on 01910
| Article | Year |
|---|---|
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gemcitabine; Glycine; Humans; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Sulfones; Survival Analysis; Treatment Outcome | 2012 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glycine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Sulfones; Tumor Suppressor Protein p53 | 2015 |
2 other study(ies) available for gemcitabine and on 01910
| Article | Year |
|---|---|
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; Cyclin B; Cyclin B1; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Glycine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Predictive Value of Tests; Sulfones; Xenograft Model Antitumor Assays | 2009 |
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Autophagy; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Glycine; Humans; Radiation-Sensitizing Agents; Sulfones | 2021 |